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Background: Depression is a common antenatal mental disorder associated with signiﬁcant maternal morbidity
and adverse fetal outcomes. However, there is a lack of research on the eﬀectiveness or cost-eﬀectiveness of
psychological interventions for antenatal depression.
Methods: A parallel-group, exploratory randomised controlled trial across ﬁve hospitals. The trial compared
Guided Self-Help, modiﬁed for pregnancy, plus usual care with usual care alone for pregnant women meeting
DSM-IV criteria for mild-moderate depression. The trial objectives were to establish recruitment/follow-up rates,
compliance and acceptability, and to provide preliminary evidence of intervention eﬃcacy and cost-eﬀective-
ness. The primary outcome of depressive symptoms was assessed by blinded researchers using the Edinburgh
Postnatal Depression Scale at 14-weeks post-randomisation.
Results: 620 women were screened, 114 women were eligible and 53 (46.5%) were randomised. 26 women
received Guided Self-Help – 18 (69%) attending ≥4 sessions - and 27 usual care; n = 3 women were lost to
follow-up (follow-up rate for primary outcome 92%). Women receiving Guided Self-Help reported fewer de-
pressive symptoms at follow-up than women receiving usual care (adjusted eﬀect size −0.64 (95%CI: −1.30,
0.06) p = 0.07). There were no trial-related adverse events. The cost-eﬀectiveness acceptability curve showed
the probability of Guided Self-Help being cost-eﬀective compared with usual care ranged from 10 to 50% with a
willingness-to-pay range from £0 to £50,000.
Conclusions and Limitations: Despite intense eﬀorts we did not meet our anticipated recruitment target. However,
high levels of acceptability, a lack of adverse events and a trend towards improvements in symptoms of de-
pression post-treatment indicates this intervention is suitable for talking therapy services.
1. Introduction
Antenatal mental disorders are common (Howard et al., 2018), with
depression aﬀecting 11% of women in early pregnancy (Howard et al.,
2018), and up to 18% of women across the pregnancy period
(Howard et al., 2014b). Antenatal depression is associated with an in-
creased risk of preterm delivery (Stein et al., 2014), postnatal maternal
psychopathology (Bick and Howard, 2010; Howard et al., 2014b;
Milgrom et al., 2008a,b), and subsequent behavioural/emotional pro-
blems in children (Stein et al., 2014). Timely antenatal mental health
interventions are therefore necessary to alleviate these adverse eﬀects.
International guidelines advocate a lower threshold for psycholo-
gical therapies and a higher threshold for psychotropic medication for
mental health problems during pregnancy, due to potential risks to the
fetus (Howard et al., 2014a). Yet, there is a paucity of research in-
vestigating the eﬀectiveness and cost-eﬀectiveness of antenatal
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interventions for one of the most common disorders - mild to moderate
depression (Sockol et al., 2011). We are aware of only one in-
dividualised randomised controlled trial (RCT) for pregnant women
with diagnosed mild to moderate depression, a pilot RCT of an eight-
session antenatal Cognitive Behavioural Therapy (CBT), delivered by
psychologists, to 54 Australian women; substantial reductions in de-
pression and anxiety were observed during pregnancy, compared to the
control group, with eﬀects maintained at nine months postpartum
(Milgrom et al., 2014).
The National Institute for Health and Care Excellence (NICE), an
organisation providing evidence-based guidance to health services in
the UK, recommends a stepped-care approach to treating perinatal
mental disorders; starting with a low-cost intervention for mild to
moderate depression - Guided Self-Help (GSH) - delivered by National
Health Service (NHS) Psychological Wellbeing Practitioners (PWPs).
GSH is a standardised psychological treatment that individuals can
work through semi-independently using step-by-step or modular in-
structions. Recent systematic reviews and meta-analyses of RCTs of
GSH for adults with depression report evidence of eﬀectiveness post-
treatment (Coull and Morris, 2011; Cuijpers et al., 2010). In the peri-
natal context, Self-Help interventions have been successfully delivered
within Australian antenatal settings (Milgrom et al., 2011). What re-
mains unclear is whether such interventions could be successfully de-
livered within psychological therapy services as well as demonstrating
cost-eﬀectiveness in reducing antenatal depression. We therefore de-
veloped an exploratory RCT to test a new form of GSH for antenatal
depression in women attending NHS maternity services in the UK,
which could be delivered by PWPs in primary care psychology services.
There were four main aims of the trial:
• To establish that the trial procedures worked (and to ﬁne tune
where necessary) so that a Phase III trial could follow;
• To evaluate if antenatal GSH was beneﬁcial in improving depressive
symptoms for women with antenatal depression;
• To evaluate if antenatal GSH had the added beneﬁt of improving
other outcomes, including post-treatment and post-delivery psy-
chological symptoms, post-delivery bonding and quality of life;
• To explore if antenatal GSH was cost-eﬀective compared to usual
care.
We hypothesised that women with mild or moderate antenatal de-
pression treated with GSH would have signiﬁcantly lower depressive
symptom scores on the Edinburgh Postnatal Depression Scale (EPDS) at
14 weeks post-randomisation compared to women with mild or mod-
erate antenatal depression receiving usual care.
2. Methods
The Depression: a trial of antenatal Guided Self-Help for women
(DAWN) trial was registered on 08/08/14 (prior to recruitment) on
ISRCTN.com (http://www.isrctn.com/ISRCTN83768230). The protocol
has been published (Trevillion et al., 2016). CONSORT reporting
guidelines for pilot and feasibility trials (Eldridge et al., 2016), the
TiDIER checklist (Hoﬀmann et al., 2014) and Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) checklist
(Husereau et al., 2013) have been completed (see Supplementary Ta-
bles 1–3).
This was a multi-centre Phase II exploratory randomised controlled
trial with two parallel groups and a primary endpoint of EPDS score at
14 weeks post-randomisation.
2.1. Oversight
The trial and protocol were approved by the Camberwell St Giles
Research Ethics Committee, London (reference: 14.LO.0597). A Trial
Management Group (set up to monitor the day-to-day running of the
trial) met approximately every eight weeks during the trial.
Independent oversight was provided by a Programme Steering
Committee (PSC). An independent Data Monitoring and Ethics
Committee (IDMEC) reviewed the progress of the trial, the accruing
data and monitored the safety of participants, and an independent Trial
Steering Committee (TSC) provided advice and oversight on the trial
conduct/progress. The PSC and IDMEC met annually and the TSC
biannually during the trial. Analyses were conducted according to a
pre-speciﬁed Statistical and Health Economics Analysis Plan which
were approved by the TSC and IDMEC (v2, approved 29/06/2017). The
trial PWPs received weekly supervision meetings from one of the au-
thors (RM).
2.2. Randomisation and blinding
A central randomisation system, provided by the UK Clinical
Research Collaboration registered at King's College London Clinical
Trials Unit, allocated participants to either Guided Self-Help plus usual
care (GSH) or to usual care alone (i.e. treatment as usual).
Randomisation, stratiﬁed by type of depression (3 levels: mild depres-
sion, moderate depression, or mixed anxiety and depression), was ap-
plied using computer-generated block-randomisation of varying sizes,
with a 1:1 allocation. Block sizes were not disclosed, to ensure con-
cealment. Trial researchers responsible for collection of outcome data
and trial statisticians were blind to treatment allocation. Eﬀectiveness
of allocation concealment (among the researchers responsible for col-
lection of outcome data) was assessed; researchers reported which arm
they believed participants to be in.
2.3. Study setting
The trial was conduted in ﬁve large National Health Service (NHS)
maternity units within South East London; these services serve ethni-
cally and socially diverse populations. The NHS is a publicly-funded
healthcare system in the UK, free at the point of use, to every legal
resident in the UK.
Abbreviations
RCT Randomised Controlled Trial
NHS National Health Service
NICE National Institute for Health and Care Excellence
CBT Cognitive Behavioural Therapy
PWP(s) Psychological Wellbeing Practitioner(s)
GSH Guided Self Help
EPDS Edinburgh Postnatal Depression Scale
PHQ-9 Patient Health Questionnaire-9
GAD-7 Generalized Anxiety Disorder scale-7
PBQ Postpartum Bonding Questionnaire
SPS Social Provisions Scale
AUDIT-C the Alcohol Use Disorders Identiﬁcation Test-C
CAS Composite Abuse Scale
SF-36 36-item Short Form Health Survey
EQ-5D-5L EuroQol measure of health-related quality of life
QALYs Quality-Adjusted Life Years
CI Conﬁdence Interval
IQR Inter-Quartile Range
DNAs Did Not Attend
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2.4. Eligibility criteria
Adult women, aged ≥16 years, who were pregnant (not exceeding
26 weeks gestation) and who met criteria for DSM-IV depression on the
Structured Clinical Interview (i.e. mild or moderate major depressive
disorder, or mixed anxiety and depressive disorder) were eligible.
Women were excluded if they were: receiving CBT or any other psy-
chological therapy; taking antidepressants; suﬀering from psychosis, a
current eating disorder, borderline personality disorder or a current
post-traumatic stress disorder; reporting current suicidality; receiving
care from secondary mental health services; unable to complete ques-
tionnaires or follow the trial workbook in English; unable to provide
informed consent.
2.5. Recruitment
Recruitment occurred between 5th January 2015 and 30th June
2016; follow-up data collection ended on 10th April 2017. Women were
recruited to the trial in one of three ways: (1) via their participation in a
related study on well-being in pregnancy (Howard et al., 2018) (REC
reference: 14/LO/0075); (2) via midwives who considered a woman
suitable for the trial; (3) through self-referral, via advertised study
posters.
Baseline trial researchers recruited and consented participants. They
provided women with a minimum of 24 hours to consider their parti-
cipation and obtained written informed consent from everyone. These
researchers communicated the group allocation to participants and, for
women allocated to GSH, arranged an appointment with the PWP to
start the intervention; a choice of locations were oﬀered for appoint-
ments (e.g. clinical trial facility/clinical room at study sites or women's
homes) (see Trevillion et al., 2016 full details on recruitment methods).
2.6. Intervention
2.6.1. Guided Self-Help (GSH) interventions for depression
GSH is delivered as part of the Improving Access to Psychological
Therapies (IAPT) programme (Clark, 2011) within NHS-commissioned
services in England. IAPT is delivered within every local health area in
England and it provides psychological treatments for people with de-
pression and anxiety. IAPT treatments conform to stepped-care clinical
guidelines produced by NICE (Clark et al., 2018). Recent data from the
IAPT programme shows that over 537,000 people are treated each year,
with the majority of treatments oﬀered comprising CBT
(NHS Digital, 2016). PWPs deliver evidence-based low intensity CBT
interventions within the IAPT programme, particularly treatments
based on GSH manuals.
2.6.2. Modiﬁed Guided Self-Help, with usual care, (GSH) for antenatal
depression
A GSH workbook was developed speciﬁcally for this trial (available
from corresponding author on request). The workbook is divided into
six chapters, including psychoeducation on antenatal depression;
managing relationships; planning for parenthood; health and lifestyle
factors. Homework tasks are included at the end of each chapter, and at
various points throughout the workbook (see Trevillion et al., 2016 for
further details on the workbook).
Four IAPT PWPs were trained to deliver the modiﬁed GSH inter-
vention; PWPs are experienced in delivering treatments based on GSH
manuals, and in supporting participants’ use of GSH manuals. The trial
GSH intervention comprised an initial session with the PWP followed
by up to eight 30-min sessions with the PWP. In addition, the PWPs
conducted a check-in session with women at six to eight weeks post-
delivery (i.e. before the post-delivery research outcomes were col-
lected); this post-delivery session did not form part of the therapeutic
programme. The initial session was delivered face-to-face; subsequent
sessions were either delivered face-to-face or by telephone, depending
on women's preferences. Based on our pilot work, a minimum dose of
four sessions was determined necessary to impact on depressive
symptoms.
2.6.3. Usual care
We recorded use of all health and social care services over the
follow-up period, as part of the economic evaluation.
2.7. Trial measures
Participant data were collected at baseline, 14 weeks post-rando-
misation and 3 months post-delivery. Key measures included:
Edinburgh Postnatal Depression Scale (EPDS) (Cox and Holden, 2003);
Patient Health Questionnaire-9 (PHQ-9) (Kroenke et al., 2001); Gen-
eralized Anxiety Disorder scale-7 (GAD-7) (Spitzer et al., 2006) and
Postpartum Bonding Questionnaire (PBQ) (Brockington et al., 2001).
Other measures included the Social Provisions Scale (SPS) (Cutrona and
Russell, 1987), Alcohol Use Disorders Identiﬁcation Test-C (AUDIT-C)
(Babor et al., 2008), questions on smoking behaviours (developed by
the study team), the Composite Abuse Scale - short version (CAS),
which measures experiences of domestic violence (Hegarty et al.,
2005), and questions relating to timing of delivery (see
(Trevillion et al., 2016) for full details on all trial measures).
A ﬁdelity rating scale was developed to rate PWPs’ adherence to the
GSH components. At completion of the trial a randomly sampled se-
lection of 20 recordings were evaluated for ﬁdelity by RM and an in-
dependent assessor (a clinical psychologist not involved in the trial);
recordings were stratiﬁed by therapist and time (ﬁrst versus second half
of the trial). Randomly generated numbers were used to select sessions
from each group, which represented initial, mid and last sessions. In
addition, the interpersonal eﬀectiveness item from the Cognitive
Therapy Scale Revised (Blackburn et al., 2001) was used as an indicator
of positive therapeutic alliance.
Process evaluation data were collected by PWPs on the mode of
delivery of GSH sessions (i.e. face-to-face or telephone) and levels of
compliance (i.e. number and length of sessions oﬀered, number of
sessions attended/not attended or cancelled). PWPs also collected the
same standardised measures, at every session, as they did within their
IAPT service: PHQ-9 (Kroenke et al., 2001), GAD-7 (Spitzer et al.,
2006), the Work & Social Adjustment Scale and Phobia Scales
(Improving Access to Psychological Therapies, 2011) (see Supplemen-
tary Table 4 and Supplementary Fig. 1 for further details).
2.8. Outcomes
2.8.1. Primary outcome
Depressive symptoms on the Edinburgh Postnatal Depression Scale
(EPDS) at 14 weeks post-randomisation.
2.8.2. Key secondary outcomes
At 14 weeks post-randomisation
1 Proportion meeting Participant Health Questionnaire- 9 (PHQ-9)
criteria for depression (i.e. score of ≥10).
2 Proportion meeting Generalised Anxiety Disorder-7 (GAD-7) criteria
for anxiety (i.e. score of ≥8).
At three months post-delivery
1 Edinburgh Postnatal Depression Scale scores.
2 Parenting stress, as measured by the Postpartum Bonding
Questionnaire (PBQ).
3. Analysis
Although this was an exploratory RCT, we carried out a sample size
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calculation using Stata's sampsi procedure to assess what preliminary
evidence we could generate on eﬃcacy. Using a two-tailed signiﬁcance
of 5% with a correlation of 0.4 between baseline and outcome EPDS
score, a two-arm parallel-group design with 52 women in each arm
gives 79% power to detect a diﬀerence of 0.5 SD using ANCOVA.
Recruiting 110 women, we would have had 66% power to detect a
diﬀerence in the caseness rate of recovery of 35% in the treatment as
usual arm versus 60% in the GSH arm.
3.1. Quantitative data analysis
Recruitment rate, loss to follow-up and withdrawals are described
using a CONSORT diagram. Patient demographics, baseline character-
istics, primary and secondary outcomes are presented using appropriate
descriptive summaries: mean and standard deviation for normally dis-
tributed measures; medians and quartiles for skewed distributions;
numbers and percentages for discrete outcomes. The primary analysis
was performed based on the intention to treat (ITT) principle. EPDS
total scores at 14 weeks post-randomisation and 3 months post-delivery
were jointly modelled using seemingly unrelated regressions (im-
plemented using the Stata sem procedure) to account for any correlation
between the two measures. This involved performing an ANCOVA on
the EPDS score at 14 weeks post-randomisation with treatment arm and
depression severity as factors and the baseline EPDS score as a cov-
ariate. Eﬀect size was calculated using the standard deviation of the
baseline EPDS over both groups; 95% conﬁdence intervals (CIs) were
calculated using bootstrapping (1000 samples used). A similar model
was used for the EPDS at 3 months post-delivery. The piecewise nature
of the model minimises the contamination of the 3-month post-delivery
estimates by the 14-week post-randomisation scores. Maximum like-
lihood with missing values (MLMV) was used for estimation.
Due to the small sample size [see results section for details], planned
supplementary analyses to estimate complier-average causal eﬀects for
a binary measure of compliance to treatment using the instrumental
variable method were not undertaken. Exact logistic regressions were
used to model the diﬀerence in proportions meeting the PHQ-9 criteria
for depression (i.e., a score ≥10) and the GAD-7 criteria for anxiety
(i.e., a score ≥8), as well as alcohol intake (“yes drinking”, “not
drinking”) on the AUDIT-C questionnaire. These were analysed at 14
weeks post-randomisation and 3 months post-delivery, with depression
severity and treatment arm included as factors, and total baseline scores
included as a covariate. Due to the small numbers of participants re-
porting smoking behaviours, domestic violence, or a premature birth
(<37 weeks) planned logistic regressions were not undertaken for these
outcomes. Planned analyses of infant height and weight were not un-
dertaken as these data were not available. The social provisions scale
(SPS) total score was analysed using an ANCOVA model that included
the baseline score. Parenting stress, as measured by the PBQ, was as-
sessed using a two-way ANOVA of the total score. SPS and PBQ analyses
included treatment arm and depression severity as factors. Due to small
numbers, individuals with mixed anxiety and depression were com-
bined with the mild depression individuals in all analyses that con-
tained the depression severity stratiﬁer (i.e. 2 levels: mild/mixed an-
xiety depression, moderate depression).
For baseline measures used as a covariate in the main modelling,
participant mean item score was used to impute missing items (for up to
30% missing items) in forming a total score (pro-rating). This was
deemed to be satisfactory as the amount of missing data was small
(approximately 1-2% of participants). No imputation was performed for
participants who had >30% missing data in a questionnaire. Missing
data in post-randomisation outcome variables were accounted for
under the Missing-at-Random assumption of maximum likelihood. All
statistical analyses were performed in Stata (v14).
3.2. Economic evaluation
A cost-eﬀectiveness analysis was conducted at the 3-month post-
delivery follow-up point taking an NHS/Personal Social Services per-
spective preferred by NICE (National Institute for Health and Care
Excellence, 2008). Quality-Adjusted Life Years (QALYs) were calculated
using the SF-6D measure of health-related quality of life, derived from
the 36 item Short Form Health Survey (SF-36) (Ware, 2000), which was
completed by participants at baseline, and at the 14-week post-rando-
misation and 3-month post-delivery follow-up points.
Data on the number of contacts participants in the GSH arm re-
ceived from PWPs was recorded using a proforma, completed by the
PWPs, which included the number and duration of sessions for each
participant. To account for the ratio of direct face-to-face to indirect
non-face-to-face time (preparation, administration, supervision etc.) a
proforma was completed by the PWPs to record time spent on diﬀerent
activities in a typical week; this was used to estimate additional time
associated with each face-to-face contact. Data on the use of all other
health and social care services were collected using the Adult Service
Use Schedule (AD-SUS) adapted for this study to cover all hospital and
community-based health and social care services for both participants
and their index baby (post-birth) (Howard, 2011; Howard et al., 2010).
The AD-SUS was completed in interview at both follow-up points and
covered the period from baseline to the 14-week post-randomisation
interview and from the 14-week post-randomisation interview to the 3-
month post-delivery interview, respectively. Total costs were calculated
by applying unit costs to resource use at the individual level. Nationally
applicable unit costs were applied to all services (see online supplement
for additional details). All costs are reported in pounds sterling at 2015/
2016 prices. Discounting was not relevant as the follow-up did not
exceed 12 months.
Diﬀerences in mean costs and outcomes were obtained by non-
parametric bootstrap regressions (10,000 repetitions, bias-corrected) to
account for non-normally distributed data commonly found in eco-
nomic data (Thompson and Barber, 2000). To provide more relevant
treatment-eﬀect estimates (Assmann et al., 2000), regressions to cal-
culate mean diﬀerences in costs included baseline variables which
could inﬂuence cost over the follow-up, including depression stratiﬁer
(deﬁned as mild depression or mixed depression and anxiety versus
moderate depression) and the baseline variable of interest, where
available. The primary economic analysis excluded patients with
missing cost or outcome data.
Cost-eﬀectiveness was explored with the net beneﬁt approach. We
calculated area under the curve values for QALYs with linear inter-
polation between assessments (Manca et al., 2005). We used cost-ef-
fectiveness acceptability curves to explore uncertainty around costs and
cost-eﬀectiveness due to sampling variation and the maximum cost-
eﬀectiveness ratio that a decision maker would deem acceptable
(Fenwick and Byford, 2005). The curves were created from boot-
strapped costs and eﬀects to calculate the probability of each treatment
being the optimum choice, subject to a range of possible maximum
values that a decision maker might be willing to pay for an increase in
QALYs.
A secondary analysis was performed substituting the SF-6D with the
5-dimension, 5-level version of the EuroQol measure of health-related
quality of life (EQ-5D-5L) (Herdman et al., 2011). Sensitivity analyses
included: a narrow perspective including mental health services only in
order to control for the fact that many services used in the postpartum
period may be unrelated to mental health and the intervention under
investigation; replacing the proportion of direct to indirect time spent
by PWPs with published estimates (1:1;(Curtis and Burns, 2015)); and
removing outliers and inﬂuential observations (see Supplementary In-
formation 3 for full details on the economic evaluation methods).
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4. Results
4.1. Aim one: to establish that the trial procedures worked
See Table 1 for the demographic details of the n = 53 participants
and Table 2 for the baseline clinical characteristics of participants.
Overall the two groups had similar characteristics, except for annual
income; the usual care arm had considerably higher annual incomes
than the intervention arm (annual income ≥£46,000 of 70% versus
24%, respectively).
4.2. Recruitment and retention
We recruited n = 53 women: 26 participants were randomly allo-
cated to GSH and 27 randomly allocated to usual care. Three partici-
pants were lost to follow-up at 14 weeks post-randomisation (two from
the GSH arm and one from the usual care only arm); four participants
were lost to follow-up at 3 months post-delivery (two from each arm).
No participants withdrew from the trial (See Fig. 1 for full details).
Despite intensive eﬀorts, we did not reach our recruitment target of
n = 110 participants. We implemented several diﬀerent strategies to
enhance recruitment, including: trial researchers working evenings and
weekends to ﬁt in with women's work/childcare commitments; trial
researchers and PWPs conducting home visits; the trial team attending
expectant parent workshops and antenatal staﬀ meetings to advertise
the study; extending recruitment by three months. The trial team also
sought advice and guidance from their lived experience advisory group
on ways to enhance recruitment. At the beginning of the trial, ﬁndings
of local audits and a recent study (Burns et al., 2013) indicated that
very few pregnant women were referred for psychological therapy in
routine practice. However, during the trial substantial national policies
and developments for perinatal IAPT services occurred. Local IAPT
services subsequently became more proactive in facilitating access by
pregnant women and midwives made more referrals to IAPT; these
policy and practice changes are likely to have reduced our ability to
recruit women. We saw recruitment tail oﬀ around the end of December
2015 and, after a few more months of intense eﬀorts, we took the de-
cision to close recruitment on 30th June 2016.
4.3. Levels of compliance with the intervention
18 participants (69%) attended at least the minimum number of
sessions (≥4 sessions) and eight (31%) did not. All eight ‘non-com-
pleters’ remained in the study and their reasons for withdrawal from
treatment included: inconvenience of the intervention alongside ex-
isting commitments (n = 3); intervention no longer needed as symp-
toms resolved (n= 2); disengagement (n= 2). The 18 participants who
attended≥4 sessions also attended the additional post-delivery session;
only one of the non-completers (who did not withdraw from treatment)
attended this session.
The overall median number of sessions attended was 6.5 (IQR 3–8;
range 0–8). For completers the median number of sessions attended was
7 (IQR 6–8; range 4–8) for non-completers the median number of ses-
sions attended was 1.5 (IQR 0–3; range 0–3). Three participants did not
attend any GSH sessions.
There were 231 scheduled appointments, of which 157 (68%) were
attended, 65 (28%) were cancelled, and 9 (4%) were not attended
(DNAs). Of the attended sessions, 115 (73%) were face-to-face and 42
(27%) were by telephone. In 64% of sessions relevant chapter reading
of the workbook had been completed and in 41% of sessions all
homework had been completed.
4.4. Treatment ﬁdelity and therapeutic alliance
Fidelity ratings were high; a median score of 100% (IQR:
100%–100%; range: 67%–100%) was achieved across 16 randomly
selected sessions. PWPs demonstrated competence with regards to in-
terpersonal eﬀectiveness, achieving a median score of 3 (IQR: 3–4;
mean 3.4).
4.5. Trial adverse events
Nine adverse events were reported, ﬁve in the usual care arm and
four in the GSH arm. None of these adverse events were related to
Table 1
Demographic details of n = 53 DAWN trial participants.
Treatment arm:
Guided Self-
Help group
Comparison
arm: Usual care
group
Overall
Age group (n = 53)
<25 3 (11.54%) 2 (7.41%) 5 (9.43%)
25–29 5 (19.23%) 3 (11.11%) 8 (15.09%)
30–39 18 (69.23%) 18 (66.67%) 36 (67.92%)
40+ 0 (0%) 4 (14.81%) 4 (7.55%)
Ethnicity (n = 53)
White 18 (69.23%) 17 (62.96%) 35 (66.04%)
Black 7 (26.92%) 7 (25.93%) 14 (26.42%)
Asian 0 (0%) 1 (3.70%) 1 (1.89%)
Mixed/Other 1 (3.85%) 2 (7.41%) 3 (5.66%)
Gestational age at
baseline visit
(n = 49)
Mean:10 weeks
(sd = 1.76)
Min: 7; Max: 15
Mean: 11.1
weeks
(sd = 2.19)
Min: 8; Max:17
Mean: 10.6
weeks
(sd = 2.06)
Min: 7; Max: 17
Employment status
(n = 53)
Working 23 (88.46%) 21 (77.78%) 44 (83.02%)
Student 1 (3.85%) 0 (0%) 1 (1.89%)
Unemployed 2 (7.69%) 2 (7.41%) 4 (7.55%)
Homemaker 0 (0%) 3 (11.11%) 3 (5.66%)
Not working due to
illness/Other
0 (0%) 1 (3.70%) 1 (1.89%)
Income (n = 45)
< £15,000 6 (24%) 1 (5%) 7 (15.56%)
£15,000–£30,999 5 (20%) 3 (15%) 8 (17.78%)
£31,000–£45,999 8 (32%) 2 (10%) 10 (22.22%)
£46,000–£60,999 0 (0%) 7 (35%) 7 (15.56%)
£61,000 or more 6 (24%) 7 (35%) 13 (28.89%)
Living situation
(n = 53)
Alone 5 (19.23%) 5 (18.52%) 10 (18.87%)
Spouse/partner 19 (73.08%) 18 (66.67%) 37 (69.81%)
Parents/family 2 (7.69%) 2 (7.41%) 4 (7.55%)
Other 0 (0%) 2 (7.41%) 2 (3.77%)
Relationship status
(n = 53)
Single 5 (19.23%) 4 (14.81%) 9 (16.98%)
Partner not cohabiting 3 (11.54%) 5 (18.52%) 8 (15.09%)
Cohabiting/ married 18 (69.23%) 18 (66.67%) 36 (67.92%)
Immigration status
(n = 53)
UK National 19 (73.08%) 17 (62.96%) 36 (67.92%)
European Economic
Area citizen
4 (15.38%) 3 (11.11%) 7 (13.21%)
Indeﬁnite leave to
remain/Exceptional
leave to remain
2 (7.69%) 4 (14.81%) 6 (11.32%)
Temporary admission/
Awaiting initial
decision
1 (3.85%) 3 (11.11%) 4 (7.55%)
Education (n = 53)
None/only school
qualiﬁcations
4 (15.38%) 4 (14.81%) 8 (15.09%)
Training/Higher
Certiﬁcate/Diploma
6 (23.08%) 8 (29.63%) 14 (26.42%)
Degree/Postgraduate 16 (61.54%) 15 (55.56%) 31 (58.49%)
Other children
(n = 53)
None
16 (61.54%) 11 (40.74%) 27 (50.94%)
1 6 (23.08%) 13 (48.15%) 19 (35.85%)
≥2 4 (15.38%) 3 (11.11%) 7 (13.21%)
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mental health or to the intervention: very preterm birth, severe asthma
attack, an incident of domestic violence, post-elective caesarean com-
plication, three postpartum haemorrhages, pre-eclampsia and neonatal
blood transfusion.
4.6. Success of blinding
The blinded follow-up researchers correctly guessed the allocation
of 50% of the GSH arm at 14 weeks post-randomisation and 32% at 3
months post-delivery. For the usual care arm, correct guesses were
made for 70% of participants at 14 weeks post-randomisation and 68%
at 3 months post-delivery.
4.7. Aim two: to evaluate if antenatal GSH was beneﬁcial in improving
depressive symptoms for women with antenatal depression
The mean EPDS score at 14 weeks post-randomisation was 9.50
(sd = 6.35) for the GSH arm, 12.27 (sd = 4.79) for the usual care arm,
and 10.94 (sd = 5.71) overall. The mean EPDS score at 3 months post-
delivery was 7.00 (sd = 4.86) in the GSH arm, 9.36 (sd = 5.33) in the
usual care arm, and 8.20 (sd = 5.19) overall.
On the EPDS, an eﬀect size of −0.64 (95%CI: −1.30, 0.06,
p = 0.07) was observed at 14-weeks post randomisation. At 3 months
post-delivery an eﬀect size of −0.39 (95%CI: −1.03, 0.25, p = 0.24)
was observed. Though the pattern of eﬀect estimates was in the di-
rection favouring GSH, these were individually non-signiﬁcant (See
Fig. 2 and Table 2 for full details).
4.8. Aim three: to evaluate if antenatal GSH had the added beneﬁt of
improving other outcomes
At 14 weeks post-randomisation, women in the GSH arm had lower
odds of meeting PHQ-9 criteria for depression (AOR: 0.49, 95%: 0.09,
2.21; p = 0.46) and lower odds of meeting GAD-7 criteria for anxiety
(AOR 0.48, 95% CI: 0.08, 2.44; p= 0.50) than women in the usual care
arm. At 3 months post-delivery, women in the GSH arm had lower odds
of meeting GAD-7 criteria for anxiety (AOR 0.37, 95% CI: 0.07, 1.71;
p = 0.25) and higher odds of meeting PHQ-9 criteria for depression
(AOR 1.47, 95% CI: 0.21, 11.71; p = 0.96) than women in the usual
care arm. These ﬁndings were all statistically non-signiﬁcant (see Fig. 3
and Table 2 for full details). In relation to parenting stress (measured
using the PBQ), the GSH arm reported higher mean parenting stress
levels than the usual care arm (eﬀect size 0.42 (95%CI: −0.15, 0.97,
p = 0.14) but the eﬀect estimates were non-signiﬁcant (See Fig. 2 and
Table 2 for full details).
On the Social Provisions Scale, at 14 weeks post-randomisation and
3 months post-delivery the GSH arm reported lower levels of perceived
social support than the usual care arm ((eﬀect size of -0.48 (95% CI:
-0.89, -0.11, p=0.02 at 14 weeks post-randomisation) / (eﬀect size of
-0.40 (95% CI: -0.85, 0.02, p=0.07 at 3 months post-delivery)) but the
observed eﬀects were non-signiﬁcant. Most other outcomes were
comparable across both arms at each time-point (see Table 2 for full
details).
Table 2
Descriptive statistics for key variables at baseline, 14 weeks post-randomisation and 3 months post-delivery for each trial arm.
Baseline 14 weeks post-
randomisation
3 months post-delivery
Guided Self Help
(plus usual care)
group
Usual care Guided Self Help (plus
usual care) group
Usual care Guided Self Help (plus
usual care) group
Usual care
Primary outcome
EPDS Median: 15 (11–18) Median:15
(11–17)
Median: 8 (4.5–15) Median: 12
(9–16)
Median: 6.5 (3–11) Median: 9 (5–13)
Min: 5; Min: 4; Minimum: 0 Minimum: 4, Minimum: 0 Minimum: 1
Max: 25 Max: 21 Maximum: 25 Maximum: 22 Maximum: 17 Maximum: 21
Secondary outcomes
PHQ-9 depression (score ≥10)
Yes 12 46.15%) 15 (57. 69%) 7 (30.43%) 11 (42.31%) 4 (16.67%) 4 (16%)
No 14 53.85%) 11 (42.31%) 16 (69.57%) 15 (57.69%) 20 (83.33%) 21 (84%)
GAD-7 anxiety (score ≥8)
Yes 13 (52%) 16 (59.26%) 6 (25%) 11 (42.31%) 5 (21.74%) 12 (48%)
No 12 (48%) 11 (40.74%) 18 (75%) 15 (57.69%) 18 (78.26%) 13 (52%)
Total Postpartum bonding
questionnaire score
NA NA NA NA Median: 6 (5–15) Median: 7 (4–9)
Minimum: 1 Minimum: 1
Maximum: 32 Maximum: 22
Other outcomes
Smoking (nowadays)
Yes 2 (7.69%) 0 (0%) 1 (4.35%) 0 (0%) 3 (12.5%) 0 (0%)
No 24 (92.31%) 27 (100%) 22 (95.65%) 26 (100%) 21 (87.5%) 24 (100%)
Drinking*
Yes 5 (20%) 2 (7.69%) 9 (39.13%) 9 (34.62%) 17 (70.83%) 16 (64%)
No 20 (80%) 24 (92.31%) 14 (60.87%) 17 (65.38%) 7 (29.17%) 9 (36%)
Domestic violence (CAS score)⁎⁎
0: 20 (90.91%) 24 (100%) 16 (84.21%) 22 (95.65%) 18 (90%) 18 (100%)
1: 2 (9.09%) 0 (0%) 2 (10.53%) 0 (0%) 1 (5%) 0 (0%)
≥2: 0 (0%) 0 (0%) 1 (5.26%) 1 (4.35%) 1 (5%) 0 (0%)
Social provisions scale (total) Median: 79.5 (71–86) Median: 82.5
(72–88)
Median: 75 (68–82) Median: 82
(74–88)
Median: 80 (72.5–90) Median: 88
(84–91)
Min: 54; Min: 59; Min: 46; Min: 65; Min:46; Min:65;
Max: 93 Max: 93 Max: 92 Max: 96 Max: 96 Max:96
⁎ For baseline, “yes” was an AUDIT baseline score ≥8; at follow-up, “yes” was an AUDIT-C score ≥1.
⁎⁎ At baseline N = 46. 6 participants indicated that they were not in a relationship since ﬁnding out that they were pregnant, and 3 patients had missing data on
the CAS score. At 14 weeks N= 42. 7 participants indicated that they were not in a relationship since the baseline interview and 4 participants had missing data. At 3
months post-delivery N = 38. 11 participants indicated that they were not in a relationship since the last interview and 4 participants had missing data.
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4.9. Aim four: to explore if antenatal GSH was cost-eﬀective compared to
usual care
Eighty-one percent (43/53) of participants had complete data for
inclusion in the case economic analyses based on SF-6D derived QALYs,
with the GSH arm having slightly fewer complete cases than the usual
care group (77% versus 85%).
The mean cost of delivering GSH was £418 (£214 SD) per partici-
pant. Total costs and SF-6D-based QALYs were similar in the two groups
at 3 months post-delivery (see Table 3). Results based on the secondary
Fig. 1. CONSORT diagram.
K. Trevillion, et al. Journal of Affective Disorders 261 (2020) 187–197
193
analysis using EQ-5D-5L-based QALYs, and results of the sensitivity
analyses did not alter the signiﬁcance of these results. Full details on the
economic evaluation results are available as supplementary informa-
tion.
The incremental cost-eﬀectiveness ratio based on QALYs calculated
from the SF-6D was £7200 per QALY (GSH was cheaper but less ef-
fective on average than usual care alone). The cost-eﬀectiveness ac-
ceptability curve based on SF-6D QALYs shows that the probability of
GSH being cost-eﬀective compared with usual care is around 50% at the
NICE preferred willingness-to-pay threshold of £20 000–£30 000 per
QALY (see Fig. 4). When based on QALYs calculated from the EQ-5D-
5L, the results were similar although the probability of GSH being cost-
eﬀective compared with usual care dropped to around 40% at the NICE
preferred willingness-to-pay threshold. When examining the cost-ef-
fectiveness based on sensitivity analyses, the probability of GSH being
cost-eﬀective compared with usual care at the NICE preferred will-
ingness-to-pay threshold was around 20% for the narrow mental health
care perspective, around 50% for the adjusted PWP indirect time ana-
lysis, and around 10% for the analysis with outliers and inﬂuential
observations removed (see supplementary information 3).
5. Discussion
This RCT is one of the ﬁrst to provide evidence on the eﬃcacy and
cost-eﬀectiveness of antenatal GSH in improving depressive symptoms
among pregnant women with DSM-IV mild to moderate depression. Our
trial procedures were feasible (aim 1): pregnant women were success-
fully randomised and retained in both arms; we achieved high levels of
compliance and treatment ﬁdelity, and no trial-related adverse events
were reported. Due to changes in NHS policy, we did not meet our
anticipated recruitment targets. GSH signalled reductions in depressive
symptoms post-treatment (aim 2) but it had mixed eﬀects in improving
other key outcomes for women (aim 3). Finally, economic analyses
indicate little diﬀerence in the costs and outcomes between the arms
(aim 4), meaning the cost-eﬀectiveness of GSH versus usual care re-
mains uncertain.
This RCT suggests that GSH can be successfully delivered to de-
pressed women in early pregnancy and this form of treatment does not
cause harm. There was a trend towards improvements in symptoms of
depression post-treatment among women who received GSH. These
ﬁndings, which are important targets for early intervention, suggest this
intervention is suitable for use in talking therapy services. Despite this,
we conclude that it is not feasible to upscale the intervention to a full
Fig. 2. Eﬀect size plot of the Edinburgh Postnatal Depression Scale (EPDS) and Postpartum Bonding questionnaire (PBQ) at each follow up time point.
Key: In each comparison, Guided Self-Help is compared to usual care alone (reference arm). A positive eﬀect size corresponds to the Guided Self-Help arm having a
larger mean; a negative eﬀect size corresponds to the usual care arm having a larger mean. For all measures, an increase in score corresponds to a worse outcome
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eﬀectiveness RCT in the UK. This is because substantial national de-
velopments were made during the running of the RCT regarding peri-
natal IAPT services, including development of new community peri-
natal service provisions. Alongside this an NHS England policy was
established, with new quality standards implemented for pregnant
women and additional funds for perinatal mental health. These devel-
opments changed local service practices; IAPT services became more
proactive in facilitating access by pregnant women, and midwives made
more referrals to IAPT. It is likely that these changes reduced our ability
to recruit to the trial; as a result, we ended the trial earlier than an-
ticipated. Nevertheless, we had minimal loss-to-follow-up across both
arms.
Among women randomised to GSH, the majority received the
minimum dose of four sessions (69%). These ﬁndings are similar to a
recent Australian RCT of an eight-session antenatal CBT intervention
for pregnant women (Milgrom et al., 2014). We found that women
receiving the intervention reported higher session attendance rates (i.e.
68%) and lower “did not attend” (DNA) rates (i.e. 4%) compared to
standard talking-therapy services (Binnie and Boden, 2016;
Richards and Borglin, 2011). Women allocated to GSH elected to re-
ceive both face-to-face and telephone-based sessions, with high levels of
therapeutic alliance reported overall. These results provide support for
research ﬁndings that levels of therapeutic alliance do not signiﬁcantly
diﬀer if CBT-based interventions are delivered face-to-face versus over
the phone (Stiles-Shields et al., 2014).
The primary economic analysis suggests little diﬀerence in the costs
and outcomes between the arms. However, sensitivity analyses taking a
narrow mental health care perspective and the removal of outliers and
inﬂuential observations suggest these results are sensitive to perspec-
tive and outliers. In this study, these two sensitivity analyses over-
lapped signiﬁcantly as the outliers were due to complications with
child-birth and thus were removed from both sensitivity analyses. The
cost-eﬀectiveness planes also demonstrate large variation driven by the
small sample size. Therefore, the cost-eﬀectiveness of GSH versus usual
care remains uncertain.
6. Limitations
Despite intense eﬀorts we did not meet our anticipated recruitment
target. Although blinded researchers only correctly identiﬁed the allo-
cation of half of the participants receiving GSH, they correctly identi-
ﬁed the allocation of 70% of participants who received usual care. The
latter ﬁnding may have resulted in possible rater bias for some usual
care arm cases. Resource use data were collected using self-report,
making it subject to participant recall bias. However, this approach was
necessary due to these data being unavailable from another single
source. Further, there is evidence that self-reported resource use is re-
liable even in populations who have cognitive deﬁcits (Calsyn et al.,
1993; Goldberg et al., 2002).
7. Conclusions
The absence of trial-related adverse events suggests that this GSH
intervention is safe to deliver to pregnant women meeting diagnostic
criteria for mild to moderate depression. In addition, observed trends in
relation to improvements in women's depressive symptoms post-treat-
ment suggests GSH is suitable for use in psychological therapy services.
Future trials of this intervention would not be feasible, due to national
policy developments, but challenges regarding participation may be
overcome if this treatment were embedded as part of routine care
within psychological therapy services.
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Fig. 4. Cost-eﬀectiveness acceptability curves for GSH versus treatment as
usual at 3 months post-delivery from the health- and social-care perspective for
SF-6D based QALYs.
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